In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.05 below Citius Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Citius Pharmaceuticals Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 3937, from total ranking in the second quarter 2026 at 4719.

Explain Quick Ratio?
How much Cash & cash equivalents CTXR�s has?
What are CTXR�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CTXR Quick Ratio	(Jun 30 2026) Q3	(Mar 31 2026) Q2	(Dec 31 2025) Q1	(Sep 30 2025) Q4	(Jun 30 2025) Q3
Y / Y Current Liabilities Change	1602.3 %	6.12 %	527.63 %	527.63 %	372.48 %
Y / Y Cash & cash equivalent Change	179.31 %	-24.62 %	30.76 %	30.76 %	-66.08 %
Quick Ratio MRQ	0.05	0.08	0.09	0.09	0.31
CTXR's Total Ranking	# 3937	# 4719	# 4531	# 3613	# 4487
Seq. Current Liabilities Change	507.01 %	22.49 %	0 %	128.95 %	-62.16 %
Seq. Cash & cash equivalent Change	270.52 %	7.95 %	0 %	-30.17 %	-0 %

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 433
Healthcare Sector	# 873
Overall Market	# 4043

Quick Ratio Statistics
High	Average	Low
34.76	3.85	0
(Mar 31 2021)		(Mar 31 2013)

Financial Statements
Citius Pharmaceuticals Inc 's Current Liabilities	$ 334 Millions	Visit CTXR's Balance sheet
Citius Pharmaceuticals Inc 's Cash & cash equivalent	$ 17 Millions	Visit CTXR's Balance sheet
Source of CTXR's Sales		Visit CTXR's Sales by Geography

Cumulative Citius Pharmaceuticals Inc 's Quick Ratio

CTXR's Quick Ratio for the trailling 12 Months

CTXR Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	458.22 %	133.92 %	612.47 %	481.03 %	331.37 %
Y / Y Cash & cash equivalent TTM Growth	61.13 %	-37.19 %	-44.18 %	-67.37 %	-77.65 %
Quick Ratio TTM	0.06	0.12	0.13	0.16	0.22
Total Ranking TTM	# 3307	# 3785	# 2888	# 2934	# 2454
Seq. Current Liabilities TTM Growth	191.13 %	1.97 %	30.57 %	44.02 %	22 %
Seq. Cash & cash equivalent TTM Growth	56.91 %	-7.25 %	5.08 %	5.35 %	-38.83 %

Quick ratio ranking by company, industry and sector >> Back to CTXR Financial Strength Comparisons >> Go to Compare CTXR Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q3 2026 to $333.95 millions, cumulative Quick Ratio decreased to 0.06 below the Citius Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 442 other companies have achieved higher Quick Ratio than Citius Pharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending second quarter 2026 at 4111.

Explain Quick Ratio?
How much Cash & cash equivalents CTXR�s has?
What are CTXR�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 443
Healthcare Sector	# 909
Within the Market	# 3937

trailing twelve months Quick Ratio Statistics
High	Average	Low
24.71	3.6	0
(Dec 31 2021)		(Dec 31 2013)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Cumberland Pharmaceuticals Inc	0.11	$ 3.862 Millions	$ 35.193 Millions
Igc Pharma Inc	0.11	$ 0.354 Millions	$ 3.287 Millions
Tuhura Biosciences Inc	0.11	$ 0.996 Millions	$ 9.255 Millions
Gridai Technologies Corp	0.10	$ 1.380 Millions	$ 14.146 Millions
Bioxcel Therapeutics Inc	0.09	$ 12.841 Millions	$ 137.149 Millions
Galectin Therapeutics Inc	0.09	$ 13.275 Millions	$ 151.619 Millions
Lftd Partners Inc	0.08	$ 0.304 Millions	$ 3.648 Millions
Processa Pharmaceuticals Inc	0.08	$ 0.196 Millions	$ 2.387 Millions
Cv Sciences Inc	0.05	$ 0.266 Millions	$ 4.943 Millions
Citius Pharmaceuticals Inc	0.05	$ 17.008 Millions	$ 333.952 Millions
Sunshine Biopharma Inc	0.05	$ 0.281 Millions	$ 5.619 Millions
Hcw Biologics Inc	0.04	$ 0.741 Millions	$ 18.648 Millions
China Pharma Holdings Inc	0.04	$ 0.305 Millions	$ 7.682 Millions
Bioxytran Inc	0.03	$ 0.177 Millions	$ 5.275 Millions
Cdt Equity Inc	0.03	$ 0.700 Millions	$ 23.351 Millions
Shuttle Pharmaceuticals Holdings Inc	0.03	$ 0.102 Millions	$ 3.481 Millions
Northwest Biotherapeutics Inc	0.01	$ 0.595 Millions	$ 42.982 Millions
Oncotelic Therapeutics Inc	0.01	$ 0.186 Millions	$ 17.907 Millions

Date modified: 2026-09-12T06:21:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.